natgillin/translations-raw huggingface dataset:
har tegn på overophedning: høj kropstemperatur, men kun lidt eller ingen svedproduktion, hurtig puls og åndedræt, muskelkramper og forvirring. har tanker om at skade Dem selv eller begå selvmord.
have signs of overheating - high body temperature but little or no sweating, rapid heartbeat and breathing, muscle cramps, and confusion. have thoughts of harming or killing yourself.
har tendens til hypoglykæmi, tidligere har haft behov for høje insulindoser grundet tilstedeværelsen af insulinantistoffer.
have a tendency to hypoglycaemia, previously required high insulin doses due to the presence of insulin antibodies.
har tendens til hypoglykæmi, tidligere havde behov for høje insulindoser pga. tilstedeværelse af insulinantistoffer.
have a tendency to hypoglycaemia, previously required high insulin doses due to the presence of insulin antibodies.
har unormalt træg afføring. har en sygdom i galdeblæren eller bugspytkirtlen.
have abnormally slow bowel movements; have a disease of the gall bladder or pancreas.
har utilstrækkelig huddækning og vaskularisering på spinal fusion-stedet; har tidligere anamnese med eksponering over for knoglemorfogenetiske protein-produkter (BMP);
have inadequate skin coverage and vascularity at the site of spinal fusion; have prior history of exposure to any bone morphogenetic protein (BMP) product;
har været eksponeret for Vibativ på et hvilket som helst tidspunkt af graviditeten,
who were exposed to VIBATIV at any time during pregnancy and shall evaluate
har været overfølsom over for det aktive indholdsstof eller over for et eller flere af hjælpestofferne
have a history of severe hypersensitivity to the active substance or to any of the excipients
har øjenproblemer såsom visse typer af grøn stær (glaukom - forøget tryk i øjet)
have eye problems, such as certain kinds of glaucoma (increased pressure in the eye)
har øjenproblemer, såsom visse typer af grøn stær (glaukom - forøget tryk i øjet)
have eye problems, such as certain kinds of glaucoma (increased pressure in the eye)
har øjenproblemer, såsom visse typer af grøn stær (glaukom - forøget tryk i øjet)
have eye problems, such as certain kinds of glaucoma (increased pressure in the eye);
Harmire Road Barnard Castle
Middlesex TW8 9GS
harmløs rødbrun misfarvning af urinen
harmless reddish-brown discolouration of urine
Harrow Middlesex HA3 OBU
Harrow Middlesex HA3 OBU.
Harvoni er et lægemiddel mod virus (et antiviralt lægemiddel), der anvendes til behandling af voksne med langvarig (kronisk) hepatitis C (en smitsom sygdom, der angriber leveren og forårsages af hepatitis C-virus).
Harvoni is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus).
Harvoni er kontraindiceret sammen med prikbladet perikon, en kraftig P-gp-inducer i tarmen (se pkt.
Harvoni is contraindicated with St. John’s wort, a potent intestinal P-gp inducer (see section 4.3).
Harvoni var genstand for tre hovedundersøgelser med i alt omkring 2 000 patienter, der var smittet med hepatitis C af genotype 1, og som ikke havde svigtende leverfunktion.
Harvoni was investigated in three main studies involving a total of around 2,000 patients infected with hepatitis C of genotype 1 who did not have failure of liver function.
Harvonis potentiale for at påvirke andre lægemidler
Potential for Harvoni to affect other medicinal products
Harzard ratio: 1,122 (97,2 %CI:0.937;1,342)*
Hazard Ratio: 1.122
Haselünne/IDT2617/2003 (H1N1) ≥ 10,22 log2 GMNU Bakum/1832/2000 (H1N2) ≥ 12,34 log2 GMNU
Haselünne/IDT2617/2003(H1N1) ≥ 10.22 log2 GMNU* Bakum/1832/2000 (H1N2) ≥ 12.34 log2 GMNU
Haselünne/IDT2617/2003 (H1N1) ≥ 10,22 log2 GMNU Bakum/1832/2000 (H1N2) ≥ 12,34 log2 GMNU
Haselünne/IDT2617/2003(H1N1) ≥ 10.22 log2 GMNU, Bakum/1832/2000 (H1N2) ≥ 12.34 log2 GMNU
Haselünne/IDT2617/2003 (H1N1) ≥ 10,22 log2 GMNU1
Haselünne/IDT2617/2003 (H1N1) ≥ 10.22 log2 GMNU1
Haselünne/IDT2617/2003 (H1N1) ≥ 10,22 log2 GMNU1 Bakum/1832/2000 (H1N2) ≥ 12,34 log2 GMNU1
Haselünne/IDT2617/2003 (H1N1) ≥ 10.22 log2 GMNU1 Bakum/1832/2000 (H1N2) ≥ 12.34 log2 GMNU1
Haselünne/IDT2617/2003 (H1N1)≥ 10,22 log2 GMNU1 Bakum/1832/2000 (H1N2) ≥12,34 log2 GMNU1
Haselünne/IDT2617/2003 (H1N1) ≥ 10.22 log2 GMNU1 Bakum/1832/2000 (H1N2) ≥ 12.34 log2 GMNU1
Hastighed
Rate
Hastighed for glucoseforbruget* (mg/kg/min)
Rate* (mg/kg/min)
Hastighed for leveret lægemiddel [mg/min]
Drug Delivery Rate [mg/min]
Hastigheden bør kun ændres, hvis de første 2 infusioner af DARZALEX var veltolererede, hvilket defineres som fravær af IRR'er > grad 1 ved en endelig infusionshastighed på ≥ 100 ml/time.
Modified rates should only be used if the first 2 infusions of DARZALEX were well-tolerated as defined by an absence of ≥ Grade 1 IRRs during a final infusion rate of ≥ 100 mL/hr.
Hastigheden for ændringer i niveauet af biomarkører såsom calcitonin (CTN) og/eller carcinoembryonalt antigen (CEA) samt hastigheden for forandringer i tumorvolumen under observation (watchful waiting) kan hjælpe med til at identificere ikke blot patienter med behov for behandlingen, men også det optimale tidspunkt for indledning af behandling med vandetanib.
Rate of change in biomarker levels such as of calcitonin (CTN) and/or carcinoembryonic antigen (CEA) as well as the rate of change of tumor volume during watchful waiting might help to identify not only patients in need for treatment but also the optimal moment to commence treatment with vandetanib.
Hastigheden for ændringer i niveauet af biomarkører såsom calcitonin (CTN) og/eller carcinoembryonalt antigen (CEA) samt hastigheden for forandringer i tumorvolumen under observation (watchful waiting)kan hjælpe med til at identificere ikke blot patienter med behov for behandlingen, men også det optimale tidspunkt for indledning af behandling med vandetanib.
Rate of change in biomarker levels such as of calcitonin (CTN) and/or carcinoembryonic antigen (CEA) as well as the rate of change of tumour volume during watchful waiting might help to identify not only patients in need for treatment but also the optimal moment to commence treatment with vandetanib.
Hastigheden og graden af amlodipin/valsartan- absorptionen er ækvivalent med valsartans og amlodipins biotilgængelighed, når de gives som individuelle tabletter.
The rate and extent of absorption of amlodipine/valsartan are equivalent to the bioavailability of valsartan and amlodipine when administered as individual tablets.
Hatfield Hertfordshire AL10 9SN
Hatfield Herts AL10 9SN
Hatfield, Hertfordshire, AL10 9SN, Storbritannien
Hatfield, Hertfordshire AL10 9SN, United Kingdom
Hatfield, Hertfordshire, AL10 9SN, Storbritannien
Hatfield, Hertfordshire, AL10 9SN, United Kingdom
Hatfield, Herts AL10 9SN Storbritannien
Hatfield, Herts AL10 9SN United Kingdom
Hav altid dette kort på dig
Keep this card with you at all times
Hav altid dette patient-informationskort på dig.
Keep this Patient Alert Card with you.
Hav altid din inhalator med anfaldsmedicin på dig og brug den til at afhjælpe pludselige anfald af åndenød og hvæsen.
Always keep your ‘reliever inhaler’ with you and use it to relieve sudden attacks of breathlessness and wheezing.
Hav altid din inhalator med hurtigtvirkende anfaldsmedicin på dig.
You should always have your fast-acting 'rescue' inhaler with you.
Hav altid din pen på dig.
Always keep your pen with you.
Hav altid en ekstra pen med dig i tilfælde af, at du mister din pen, eller den går i stykker.
Always carry an extra Pen in case yours is lost or damaged.
Hav altid en ekstra pen og nye nåle parat, hvis du taber eller beskadiger pennen eller nålene.
Always keep an extra pen and new needles, in case of loss or damage.
Hav altid en ekstra pen og nåle på dig i tilfælde af tab eller beskadigelse.
Always carry an extra pen and new needles with you, in case of loss or damage.
Hav altid en ekstra pen på dig i tilfælde af, at du mister din pen, eller den bliver beskadiget.
Always carry an extra pen in case yours is lost or damaged.
Hav altid pennen på dig.
Always keep your pen with you.
Hav altid sukker på dig.
Always carry sugar with you.
Hav spritservietter og hæfteplaster parat (medfølger ikke), hvis du har brug for dem.
Prepare alcohol wipes and sticking plasters (not supplied) if you need them.
Have kvalme med diarré og opkastning, mavesmerter eller feber (tegn på tarmproblemer).
Feeling sick (nausea) with diarrhoea and vomiting, abdominal pain or fever (signs of bowel problems).
Have kvalme med tab af appetitten, lys urin, gul hud eller øjne (tegn på leverproblemer).
Feeling sick (nausea), with loss of appetite, light-coloured urine, yellow skin or eyes (signs of liver problems).
Have kvalme med tab af appetitten, mørk urin, gul hud eller øjne (tegn på leverproblemer).
Feeling sick (nausea), with loss of appetite, dark-coloured urine, yellow skin or eyes (signs of liver problems).
Hay-on-Wye Hereford Herfordshire HR3 5PG
Hay-on-Wye Hereford Herefordshire HR3 5PG
Hay-on-Wye Hereford, HR3 5PG
Hay-on-Wye Hereford, HR3 5PG United Kingdom
Hay-on-Wye Hereford, HR3 5PG Storbritannien
Hay-on-Wye Hereford, HR3 5PG United Kingdom
Hay-on-Wye HR3 5PG Storbritannien
Hay-on-Wye HR3 5PG United Kingdom
Hazard -ratio (95% CI)
Hazard ratio (95% CI)
Hazard / odds ratio
Hazard Ratio / Odds Ratio
Hazard ratio
Hazard ratio 95% CI
hazard ratio
Hazard ratios
Hazard ratio (95 %
Hazard ratio (95% CI)
Hazard ratio (95 %
HR (95% CI)
Hazard ratio (95 % CI)
Adjusted Hazard ratio (95%CI)
Hazard ratio (95 % CI)
Hazard ratio (95% C.I.)
Hazard ratio (95 % CI) c
(95% CI)
Hazard ratio (95 % CI) c
ubcutaneous arm
Hazard ratio (95 % CI) for overlevelse var 0,653 (0,476- 0,895) for patienter med KRAS-wildtype tumorer og 0,867 (0,670-1,123) for patienter med en KRAS- mutation i tumor uden påviselig heterogeneitet i behandlingseffekt (ikke-signifikant interaktionstest).
The hazard ratio (95% CI) of overall survival was 0.653 (0.476 to 0.895) for patients with KRAS wild-type tumours and 0.867 (0.670 to 1.123) for patients with KRAS mutant tumours, with no evidence of heterogeneity in treatment effect (non-significant interaction test).
Hazard ratio (95 % CI) for progressionsfri overlevelse var 0,475 (0,362-0,623) for patienter med KRAS-wildtype tumorer og 0,525 (0,425-0,649) for patienter med KRAS-muterede tumorer.
The hazard ratio (95% CI) of progression free survival was 0.475 (0.362 to 0.623) for patients with KRAS wild-type tumours and 0.525 (0.425 to 0.649) for patients with KRAS mutant tumours.
Hazard ratio (95 % CI)a
Hazard Ratio (95% CI)a
Hazard ratio (95 % CI)b lenvatinib + everolimus vs everolimus
Hazard Ratio (95% CI)b lenvatinib + everolimus vs everolimus
Hazard ratio (95 % CI)b, e
Hazard ratio (95% CI)b, e
Hazard ratio (95 % CI)b,c
Hazard ratio (95% CI)b,c
Hazard ratio (95 % CI)c
nCR n (%)
Hazard ratio (95 % CI)c p-værdid
Hazard ratio (95% CI)c p-valued
Hazard ratio (95 % CI)†
Hazard Ratio (95% CI)
Hazard ratio (95 % KI)
Hazard ratio (95% CI)
Hazard ratio (95 % KI) p-værdi b)
Hazard Ratio (95 % CI) p-value b)
Hazard ratio (95 % KI) p-værdib)
Hazard Ratio (95 % CI) p-value b)
Hazard ratio (95 % KI)b
Hazard ratio (95% CI)b
Hazard ratio (95 % KI)b 0,646 (0,543; 0,768)
Hazard ratio (95% CI)b 0.646 (0.543; 0.768)
Hazard ratio (95 % KI)b 0,740 (0,638; 0,859)
Hazard ratio (95% CI)b 0.740 (0.638; 0.859)
Hazard ratio (95 % konfidens-
0.65 (0.44, 0.96)
Hazard ratio (95 % konfidens-
HR (95% CI)
Hazard ratio (95 % konfidensinterval) 2
Hazard Ratio (95% CI) 2
Hazard ratio (95 % konfidensinterval) 2 p-værdi 3, 4
Hazard Ratio (95% CI) 2
Hazard ratio (95 % konfidensinterval)4
Hazard Ratio (95% CI)4
Hazard ratio (95 %-KI)
Hazard ratio (95% CI)
Hazard ratio (95 %CI)
Hazard ratio (95% CI)
Hazard ratio (95%
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
Hazard ratio (95%CI)
Hazard ratio (95% CI)
Hazard ratio: (95% CI)
Hazard ratio (95% CI)
Risk Reduction
Hazard ratio (95% CI), p- værdi
Hazard Ratio (95% CI), p- value
Hazard ratio (95% CI)c p-værdid
Hazard ratio (95% CI)c p-valued
Hazard ratio (95% KI) p-værdi b)
Hazard Ratio (95 % CI) p-value b)
Hazard ratio (95% konfidensinsterval)
Hazard ratio (95% CI)
Hazard ratio (95% konfidensinterval)b
Hazard ratio (95% CI)b
Hazard ratio (99 % CI)b,c
Hazard ratio (99% CI)b,c
Hazard Ratio (edoxaban 60 mg vs. warfarin) for det primære endepunkt i centre med en lavere gennemsnitlig tid for INR i målområdet (INR TTR) for warfarin var 0,73 - 0,80 for de 3 laveste kvartiler (INR TTR ≤ 57,7 % til ≤ 73,9 %).
The Hazard Ratio (Edoxaban 60 mg vs. warfarin) for the primary endpoint in the centres with a lower average time of INR in the target range (INR TTR) for warfarin was 0.73 – 0.80 for the lowest 3 quartiles (INR TTR ≤ 57.7% to ≤ 73.9%).
Hazard Ratio (Gefitinib versusDocetaxel) og 95% CI
Hazard Ratio (Gefitinib versus Docetaxel) and 95% CI
Hazard ratio (HR) (95 % CI)
Hazard Ratio (HR) (95%CI)
Hazard ratio (HR) (catumaxomab versus catumaxomab + prednisolon)
Hazard ratio (HR) (Catumaxomab versus Catumaxomab + Prednisolone)
Hazard ratio (HR) for OS var 0,66 (95 % CI: 0,51; 0,87; p = 0,0026) til fordel for ipilimumab monoterapi sammenlignet med gp100.
The hazard ratio (HR) for comparison of OS between ipilimumab monotherapy and gp100 was 0.66 (95% CI: 0.51, 0.87; p = 0.0026).
Hazard ratio (POM+LD-Dex:HD-Dex) [tosidet 95 % CIc]
Hazard Ratio (Pom+LD-Dex:HD-Dex) [Two sided 95% CIc]
Hazard ratio (risikoratio) (95 % CI)
Hazard ratio (95% CI)
Hazard ratio (risikoratio) for generel overlevelse var 1,43 (95 % CI: 1,11; 1,83).
The hazard ratio for overall survival was 1.43 (95% CI: 1.11, 1.83).
Hazard ratio (stratificeret*)
Hazard ratio (stratified*)
Hazard ratio (sunitinib vs IFN-) 0,5268
Hazard ratio (sunitinib vs IFN-) 0.5268
Hazard ratio (sunitinib vs IFN-) 0,8209
Hazard ratio (sunitinib vs IFN-) 0.8209
Hazard ratio 0,42
Hazard ratio 0.42
Hazard ratio 0,45 (95% Cl 0,22-0,89)
Hazard ratio 0.45 (95% Cl, 0.22-0.89)
Hazard ratio 0,46 (95% Cl 0,32-0,65)
Hazard ratio 0.46 (95% Cl, 0.32-0.65)
Hazard ratio 0,46, CI95% 0,33; 0,64, p<0,001
Hazard ratio 0.46, CI95% 0.33; 0.64, p<0.001
Hazard ratio 0,58, CI95% 0,43; 0,73, p<0,001
Hazard ratio 0.58, CI95% 0.43; 0.73, p<0.001
Hazard ratio 0,59
Hazard ratio 0.59
Hazard ratio 95 % CI
Hazard ratio 95% CI
Hazard ratio 95 % CI
Median survival (months)
Hazard ratio 95 %CI
Hazard ratio 95% CI
Hazard ratio 95% CI
Median time to response
Hazard ratio < 1: Stivarga er bedre end placebo
Hazard ratio < 1 favours Stivarga
Hazard ratio <1 favoriserer enzalutamid NR, ikke nået.
Hazard ratio <1 favours enzalutamide NR, not reached.
Hazard ratio <1: Stivarga er bedre end placebo
Hazard ratio < 1 favors Stivarga
Hazard Ratio = 0,35 95% CI [0,27, 0,45]
Hazard Ratio = 0.35 95% CI [0.27, 0.45]
Hazard ratio = 0,45 95% CI [0,38, 0,54]
Hazard Ratio = 0.45 95% CI [0.38, 0.54]
Hazard ratio [95 %
Hazard ratio [95% CI] 2
Hazard ratio blev beregnet efterfølgende; for alle kardiovaskulære hændelser, HR=0,91 (95 % CI, 0,62 til 1,34); for MACE, HR=0,52 (95 % CI, 0,31 til 0,90).
Hazard ratios were calculated post- hoc; for all CV events, HR=0.91 (95% CI, 0.62 to 1.34); for MACE, HR=0.52 (95% CI, 0.31 to 0.90).
Hazard ratio fluticasonpropionat/salmeterol 500/50 vs. enkeltkomponenterne (CI'er) p-værdi
Hazard Ratio fluticasone propionate/salmeterol 500/50 vs components (CIs) p value
Hazard ratio for OS var 0,772 (95 % CI 0,423; 1,408; p = 0,199; median-OS blev ikke nået i nogen af armene); 85 % af de patienter, der til at begynde med blev randomiseret til placeboarmen, fik behandling med regorafenib efter progression (se tabel 7, figur 3).
The HR for OS was 0.772 (95% CI, 0.423, 1.408; p = 0.199; median OS not reached in either arm); 85% of patients initially randomized to the placebo arm received post-progression treatment with regorafenib (see Table 7, Figure 3).
Hazard ratio for overlevelse efter intravenøs topotecan i forhold til CAV var 1,04 (95 % CI: 0,78 og 1,40).
The hazard ratio for survival of IV topotecan relative to CAV was 1.04 (95% CI 0.78 – 1.40).
Hazard ratio for patienter med EGFR-positive tumorer var 0,68 (95 % konfidensinterval 0,49-0,94) og 0,93 (95 % konfidensinterval (0,63-1,36) for patienter med EGFR-negative tumorer (defineret ved IHC under anvendelse af EGFR pharmDx kit og definerende EGFR-negativ som farvning af mindre end 10 % af tumorcellerne).
CI 0.49-0.94) for patients with EGFR-positive tumours and 0.93 (95% CI 0.63-1.36) for patients with EGFR-negative tumours (defined by IHC using EGFR pharmDx kit and defining EGFR-negative as less than 10% tumour cells staining).
Hazard ratio for patienter med EGFR-positive tumorer var 0,68 (95 % konfidensinterval 0,49-0,94) og 0,93 (95 % konfidensinterval (0,63-1,36) for patienter med EGFR-negative tumorer (defineret ved IHC under anvendelse af EGFR pharmDx kit og definerende EGFR-negativ som farvning af mindre end 10 % tumorcellerne).
CI 0.49-0.94) for patients with EGFR-positive tumours and 0.93 (95% CI 0.63-1.36) for patients with EGFR-negative tumours (defined by IHC using EGFR pharmDx kit and defining EGFR-negative as less than 10% tumour cells staining).
Hazard ratio for samlet overlevelse var 0,94 (95 % konfidensinterval: 0,89; 1,00: p = 0,0489).
The hazard ratio for overall survival was
Hazard ratio for telmisartan vs. ramipril var 1,01 (97,5 % CI 0,93-1,10; p (non- inferioritet) = 0,0019 ved en margin på 1,13).
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Hazard ratio for telmisartan vs. ramipril var 1,01 (97,5 % CI 0,93-1,10; p (non-inferioritet) = 0,0019 ved en margin på 1,13).
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Hazard ratio for telmisartan vs. ramipril var 1,01 (97,5% CI 0,93-1,10, p (non- inferioritet) =0,0019 ved en margin på 1,13).
The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Hazard ratio med 95% konfidensinterval Log-rank-test
Hazard ratio with 95% confidence interval log-rank test
Hazard Ratio P-værdi
Hazard Ratio P Value
Hazard ratio sammenlignet med enoxaparin
Risk ratio over enoxaparin
Hazard ratio sammenlignet med warfarin (95 % CI)
Hazard ratio over warfarin (95 % CI)
Hazard ratio sammenlignet med warfarin (95 % CI)
Hazard ratio vs. warfarin (95 % CI)
Hazard ratio sammenlignet med. warfarin (95 % CI)
Hazard ratio vs. warfarin (95 % CI)
Hazard ratio var 0,415 (95% CI: 0,320 - 0,539, p-værdi <0,001).
0.415 (95% CI: 0.320 - 0.539, p-value <0.001).
Hazard ratio var 0,61 (95 % konfidensinterval 0,56; 0,66).
691 days (95% CI 638;754) with a hazard ratio of 0.61 (95% CI 0.56; 0.66).
Hazard ratio var 0,61 (95 % konfidensinterval 0,56; 0,66).
754) with a hazard ratio of 0.61 (95% CI 0.56; 0.66).
Hazard ratio versus AC→P (95
Hazard Ratio versus AC→P (95% CI)
Hazard ratio vs placebo-arm (95 % konfidensinterval)
Hazard ratio vs placebo arm (95% CI)
Hazard ratio vs warfarin (95 % konfidensinterval)
Hazard ratio vs warfarin (95% confidence interval)
Hazard ratio vs. placebo (95 % konfidensinterval)
Hazard Ratio vs placebo (95% confidence interval)
Hazard ratio vs. placebo (CI'er) p-værdi
Hazard Ratio vs Placebo (CIs) p value
Hazard ratio vs. warfarin (95 % konfidensinterval)
Hazard ratio vs warfarin (95% confidence interval)
Hazard ratio*
Hazard
Hazard ratio*
Overall
Hazard ratio* (95 % CI)
Hazard ratio* (95% CI)
Hazard ratio* (HR) (95% konfidensinterval, CI)
Hazard ratio* (95% CI)
Hazard ratio** (95 % KI) 0,425 (0,347; 0,522)
Hazard ratio** (95% CI) 0.425 (0.347; 0.522)
Hazard ratio** (95 % KI) 0,752 (0,606; 0,934)
Hazard ratio** (95% CI) 0.752 (0.606; 0.934)
Hazard ratio** (95 % KI) 0,806 (0,697; 0,931)
Hazard ratio** (95% CI) 0.806 (0.697; 0.931)
Hazard ratio-estimat er baseret på en Cox-model stratificeret efter IPI-risiko og sygdomsstadie.
Hazard ratio estimate is based on a Cox’s model stratified by IPI risk and stage of disease.
Hazard ratio: (95 % CI)
Hazard ratio: (95% CI)
Hazard Ratio: 1,032
Hazard Ratio: 1.032
Hazard ratio: 1,032 (95 %CI:0,876;1,216)
Hazard Ratio: 1.032
Hazard Ratio: 1,122
Hazard Ratio: 1.122
Hazard ratio: 1,122 (97,2 % CI: 0.937;1,342)*
[95% CI: -1.1; 12.0]
Hazard ratio: 1,122 (97,2 %CI:0.937;1,342)*
Hazard Ratio: 1.122
Hazard ratioa (95% CI), p- værdib
Hazard Ratioa (95% CI), p- valueb
Hazard ratioa 0,73 (95,92% CI) (0,59; 0,89) p-værdib 0,0015
Hazard ratioa 0.73 (95.92% CI) (0.59, 0.89) p-valueb 0.0015
Hazard ratiob (95 % CI)
Hazard ratiob (95% CI)
Hazard ratioen kan overføres til en absolut gavnlig effekt udtrykt i en 3-års sygdomsfri estimeret overlevelse på 11,8 procentpoint (87,2 % versus 75,4 %) til fordel for AC→PH (Herceptin)-armen.
The hazard ratio translates into an absolute benefit, in terms of 3-year disease-free survival rate estimates of 11.8 percentage points (87.2 % versus 75.4 %) in favour of the AC→PH (Herceptin) arm.
Hazard ratioer for progressionsfri overlevelse efter Binet stadium (ITT) - median observationstid: 48,1 måneder
Hazard ratios of progression-free survival according to Binet stage (ITT) – 48.1 months median observation time
Hazard- ratio (95% CI)
Hazard ratio (95% CI)
Hazard-ratio (95 % CI) c
Hazard ratio (95% CI)c
Hazard-ratio (95% CI)
Hazard ratio (95% CI)
Hazard-ratio for progressionsfri overlevelse var 0,76 (0,63 til 0,91) for ECOG performance status 0 og 0,75 (0,61 til 0,92) for ECOG performance status 1.
The hazard ratio (95% CI) of progression free survival was 0.76 (0.63 to 0.91) for ECOG performance status 0 and 0.75 (0.61 to 0.92) for ECOG performance status 1.
Hazard-ratiob (95 % CI)
Hazard ratiob (95% CI)
HbA1c (%) i uge 121
HbA1c (%) at week 121
HbA1c (%) i uge 18
HbA1c (%) at week 18
HbA1c (%) i uge 18a
HbA1c (%) at week 18a
HbA1c (%) i uge 52b
HbA1c (%) at week 52b
HbA1c (%) i uge 78
HbA1c (%) at week 78
HbA1c (%) ved uge 121
HbA1c (%) at week 121
HbA1c (%) ved uge 18
HbA1c (%) at week 18
HbA1c (%) ved uge 241
HbA1c (%) at week 241
HbA1c (%) ved uge 78
HbA1c (%) at week 78
HbA1c (%) ændring fra baseline
HbA1c (%) change from base line
HbA1c (glykosyleret hæmoglobin) er et stof i blodet, der fortæller, hvor godt blodsukkeret er reguleret.
HbA1c (glycosylated haemoglobin) is a substance in the blood which gives an indication of how well the blood glucose is controlled.
HbA1c -reduktionen var signifikant ved administration én gang dagligt, uanset om Lyxumia blev givet morgen eller aften.
The HbA1c reduction was significant with once-daily administration, whether administered morning or evening.
HbA1c < 7 % (LOCF)d
Na 151 145 108 108
HbA1c < 8,0%) opretholdt hos 69% af patienterne behandlet med pioglitazon sammenlignet med 50% af patienterne behandlet med gliclazid.
HbA1c < 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide.
HbA1c er et stof i blodet (glykosyleret hæmoglobin), der fortæller, hvor godt blodsukkeret er reguleret.
HbA1c is a substance in the blood which gives an indication of how well the blood glucose is controlled.
HbA1c giver en indikation af, hvor godt blodglukosen reguleres.
HbA1c gives an indication of how well the blood glucose is controlled.
HbA1c resultater i placebo-kontrollerede monoterapi- og kombinationsterapi- undersøgelser*
HbA1c results in placebo-controlled monotherapy and combination therapy studies
HbA1c resultater i placebo-kontrollerede monoterapi-og kombinationsterapi- undersøgelser*
HbA1c results in placebo-controlled monotherapy and combination therapy studies
HbA1c resultater i placebokontrollerede monoterapi- og kombinationsterapiundersøgelser*
HbA1c results in placebo-controlled monotherapy and combination therapy studies
HbA1c resultater i placebokontrollerede monoterapi-og kombinationsterapiundersøgelser*
HbA1c results in placebo-controlled monotherapy and combination therapy studies
HbA1c sammenlignet med kontrol blev også observeret uanset baggrundsbehandling ved baseline.
Clinically meaningful reductions in HbA1c compared to control were also observed regardless of baseline background medication dose.
HbA1C var stabilt hos både duloxetin-behandlede og placebo-behandlede patienter.
HbA1c was stable in both duloxetine-treated and placebo-treated patients.
HbA1C var stabilt hos både duloxetin-behandlede og placebobehandlede patienter.
HbA1c was stable in both duloxetine-treated and placebo-treated patients.